Near Infrared Imaging for Lung Cancer

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Lung CancerNear Infrared Imaging - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing if surgeons can find and remove the first lymph node that a tumor drains into. Doing this could help improve the ability to find and remove all tumor cells.

Eligible Conditions
  • Lung Cancer

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 0 Secondary · Reporting Duration: 3 years

3 years
To evaluate the safety and efficacy of near-infrared technology to guide therapeutic sentinel lymph node dissection in patients with lung cancer.

Trial Safety

Safety Progress

1 of 3

Trial Design

1 Treatment Group

Near Infrared Imaging
1 of 1

Experimental Treatment

57 Total Participants · 1 Treatment Group

Primary Treatment: Near Infrared Imaging · No Placebo Group · Phase 1

Near Infrared Imaging
Drug
Experimental Group · 1 Intervention: Near Infrared Imaging · Intervention Types: Drug
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Indocyanine green
FDA approved

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 3 years

Who is running the clinical trial?

Dana-Farber Cancer InstituteLead Sponsor
1,016 Previous Clinical Trials
393,741 Total Patients Enrolled
Brigham and Women's HospitalOTHER
1,480 Previous Clinical Trials
9,735,724 Total Patients Enrolled
Beth Israel Deaconess Medical CenterOTHER
778 Previous Clinical Trials
844,376 Total Patients Enrolled
Massachusetts General HospitalOTHER
2,703 Previous Clinical Trials
30,853,151 Total Patients Enrolled
Yolonda L. Colson, MD, PhDPrincipal InvestigatorMassachusetts General Hospital

Eligibility Criteria

Age 18+ · All Participants · 5 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you: